The Goldman Sachs Group Lowers GoodRx (NASDAQ:GDRX) Price Target to $5.00

GoodRx (NASDAQ:GDRX) had its target price dropped by analysts at The Goldman Sachs Group from $6.00 to $5.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 14.68% from the stock’s previous close.

GDRX has been the subject of a number of other research reports. Citigroup cut their price objective on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a report on Friday, January 10th. Wells Fargo & Company reduced their price target on GoodRx from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Tuesday, April 29th. Finally, Truist Financial dropped their price objective on GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a report on Thursday, April 10th. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.60.

GoodRx Stock Up 2.8 %

Shares of GDRX opened at $4.36 on Friday. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -145.33, a PEG ratio of 2.46 and a beta of 1.24. GoodRx has a 52 week low of $3.68 and a 52 week high of $9.26. The stock’s 50-day moving average price is $4.49 and its 200-day moving average price is $4.73. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. The business had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.08 EPS. On average, sell-side analysts predict that GoodRx will post 0.13 EPS for the current year.

Hedge Funds Weigh In On GoodRx

A number of institutional investors and hedge funds have recently bought and sold shares of the business. National Bank of Canada FI lifted its stake in GoodRx by 34.9% in the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock worth $39,000 after purchasing an additional 2,151 shares in the last quarter. Hohimer Wealth Management LLC boosted its stake in GoodRx by 8.2% during the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company’s stock worth $155,000 after buying an additional 2,658 shares during the last quarter. SBI Securities Co. Ltd. grew its holdings in GoodRx by 13.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company’s stock valued at $100,000 after buying an additional 2,748 shares in the last quarter. Gotham Asset Management LLC increased its stake in shares of GoodRx by 31.0% in the 4th quarter. Gotham Asset Management LLC now owns 17,677 shares of the company’s stock worth $82,000 after acquiring an additional 4,182 shares during the last quarter. Finally, Gagnon Securities LLC raised its holdings in shares of GoodRx by 9.9% during the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company’s stock worth $325,000 after acquiring an additional 6,266 shares during the period. 63.77% of the stock is currently owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.